Mr John Kokkinos

Mr John Kokkinos

Casual Academic
Medicine & Health
Faculty Office

John is a Post-Doctoral Research Fellow developing new therapeutic strategies for pancreatic cancer at UNSW Sydney. He is supervised by Professor Phoebe Phillips in the Lowy Cancer Research Centre. John completed his PhD in 2022 at UNSW, entitled: 'Reprogramming Pancreatic Cancer Cells to Surrender to Microenvironmental Death Signals'. His PhD was supported by the highly prestigious UNSW Scientia PhD Scholarship and won multiple awards including Winner of the 2019 UNSW 3-Minute Thesis Competition, and has presented his work in several high impact publications and at national and international conferences. John was awarded a grant from Tour de Cure where he established and characterised a world-first model of growing human pancreatic tumours in the lab.

  • Book Chapters | 2024
    Kokkinos J; Sharbeen G; Phillips PA, 2024, 'Management of Primary Pancreatic Cancer', in Jankowski JAZ (ed.), Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach, Wiley, pp. 386 - 406, http://dx.doi.org/10.1002/9781119756422.ch20
  • Journal articles | 2024
    Netto KG; Chiang S; Kokkinos J; Haghighi KS; Raina A; Pitiyarachchi O; Youkhana J; Truong Q; Wenholz D; Li X; Laczka O; Kumar N; Wilkinson J; Goldstein D; Sharbeen G; Phillips PA, 2024, 'Abstract B062: CRO67 has therapeutic potential against pancreatic tumor cells and cancer associated fibroblasts', Cancer Research, 84, pp. B062 - B062, http://dx.doi.org/10.1158/1538-7445.panca2023-b062
    Journal articles | 2024
    van der Woude H; Phan K; Kenwright DN; Goossens L; Hally KE; Currie MJ; Kokkinos J; Sharbeen G; Phillips PA; Henry CE, 2024, 'Development of a long term, ex vivo, patientderived explant model of endometrial cancer', PLoS ONE, 19, http://dx.doi.org/10.1371/journal.pone.0301413
    Journal articles | 2022
    Kokkinos J; Sharbeen G; Haghighi KS; Youkhana J; Raina A; Pitiyarachchi O; Truong Q; Wenholz D; Laczka O; Kumar N; Goldstein D; Phillips PA, 2022, 'Abstract C073: CRO-67 is a novel therapeutic for pancreatic cancer: Implications for tumor and stromal reprogramming', Cancer Research, 82, pp. C073 - C073, http://dx.doi.org/10.1158/1538-7445.panca22-c073
    Journal articles | 2022
    Kokkinos J; Sharbeen G; Youkhana J; Boyer C; Goldstein D; Haghighi KS; McCarroll JA; Phillips PA, 2022, 'Abstract B076: βIII-Tubulin is a brake on extrinsic cell-death in pancreatic cancer', Cancer Research, 82, pp. B076 - B076, http://dx.doi.org/10.1158/1538-7445.panca22-b076
    Journal articles | 2021
    Kokkinos J; Ignacio RM; Haghighi K; Kopecky C; Sharbeen G; Gonzales-Aloy E; Youkhana J; Butler L; Goldstein D; McCarroll J; Phillips P, 2021, 'Patient-derived pancreatic tumours in a dish: implications for real-time precision medicine', HPB, 23, pp. S235 - S235, http://dx.doi.org/10.1016/j.hpb.2020.11.590
    Journal articles | 2021
    Kokkinos J; Jensen A; Sharbeen G; McCarroll JA; Goldstein D; Haghighi KS; Phillips PA, 2021, 'Does the microenvironment hold the hidden key for functional precision medicine in pancreatic cancer?', Cancers, 13, http://dx.doi.org/10.3390/cancers13102427
    Journal articles | 2021
    Kokkinos J; Sharbeen G; Haghighi KS; Ignacio RMC; Kopecky C; Gonzales-Aloy E; Youkhana J; Timpson P; Pereira BA; Ritchie S; Pandzic E; Boyer C; Davis TP; Butler LM; Goldstein D; McCarroll JA; Phillips PA, 2021, 'Ex vivo culture of intact human patient derived pancreatic tumour tissue', Scientific Reports, 11, pp. 1944, http://dx.doi.org/10.1038/s41598-021-81299-0
    Journal articles | 2021
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2021, 'Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to slc7a11 inhibition', Cancer Research, 81, pp. 3461 - 3479, http://dx.doi.org/10.1158/0008-5472.CAN-20-2496
    Journal articles | 2020
    Kokkinos J; Ignacio RMC; Sharbeen G; Boyer C; Gonzales-Aloy E; Goldstein D; McCarroll JA; Phillips PA, 2020, 'Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs', Biomaterials, 240, http://dx.doi.org/10.1016/j.biomaterials.2019.119742
    Journal articles | 2020
    Kokkinos J; Sharbeen G; Haghighi K; Ignacio RM; Kopecky C; Gonzales-Aloy E; Youkhana J; Pandzic E; Boyer C; Davis T; Butler L; Goldstein D; McCarroll J; Phillips P, 2020, 'Bringing the pancreas patient back to the bench: Ex vivo culture of intact human patient derived pancreatic tumour tissue', , http://dx.doi.org/10.1101/2020.07.30.223925
    Journal articles | 2019
    Ong KL; Campbell S; Wu BJ; McClelland RL; Kokkinos J; Szklo M; Polak JF; Allison MA; Rye KA, 2019, 'Relationship of fibroblast growth factor 21 with subclinical atherosclerosis and cardiovascular events: Multi-Ethnic Study of Atherosclerosis', Atherosclerosis, 287, pp. 46 - 53, http://dx.doi.org/10.1016/j.atherosclerosis.2019.06.898
    Journal articles | 2019
    Ong KL; McClelland RL; Allison MA; Kokkinos J; Wu BJ; Barter PJ; Rye KA, 2019, 'Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis', Atherosclerosis, 281, pp. 200 - 206, http://dx.doi.org/10.1016/j.atherosclerosis.2018.10.011
    Journal articles | 2017
    Kokkinos J; Tang S; Rye KA; Ong KL, 2017, 'The role of fibroblast growth factor 21 in atherosclerosis', Atherosclerosis, 257, pp. 259 - 265, http://dx.doi.org/10.1016/j.atherosclerosis.2016.11.033
  • Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Data from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.c.6512931
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Data from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.c.6512931.v1
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Figure S1 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428180
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Figure S1 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428180.v1
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Figure S2 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428177
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Figure S2 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428177.v1
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Figure S3 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428168
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Figure S3 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428168.v1
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Figure S4 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428165
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Figure S4 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428165.v1
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Supplementary Table 1 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428162
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Supplementary Table 1 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428162.v1
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Supplementary Table 2 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428159
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Supplementary Table 2 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428159.v1
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Supplementary Table 3 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428156
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Supplementary Table 3 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428156.v1
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Supplementary Table 4 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428153
    Other | 2023
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2023, Supplementary Table 4 from Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition, http://dx.doi.org/10.1158/0008-5472.22428153.v1
    Conference Papers | 2022
    Kokkinos J; Sharbeen G; Haghighi KS; Youkhana J; Raina A; Pitiyarachchi O; Truong Q; Wenholz D; Laczka O; Kumar N; Goldstein D; Phillips PA, 2022, 'CRO-67 is a novel therapeutic for pancreatic cancer: Implications for tumor and stromal reprogramming.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, pp. 161 - 161, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 13 September 2022 - 16 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000899825600205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Preprints | 2022
    Kokkinos J; Sharbeen G; Ignacio RM; Pandzic E; Youkhana J; Boyer C; Haghighi K; Gunawarman M; Goldstein D; Gebski V; Pajic M; Pitiyarachchi O; Davis M; Schulstad G; Arkell OSM; Kopecky C; Gonzales-Aloy E; Erkan M; Morton J; Kavallaris M; Gunning P; Hardeman E; Johns A; Gill A; Whan R; Mawson A; McCarroll J; Phillips P; Australian Pancreatic Cancer Genome Initiative , 2022, βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer, http://dx.doi.org/10.1101/2022.09.29.510034
    Preprints | 2020
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey S; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill A; Gonzales-Aloy E; Kokkinos J; Gebski V; Turner N; Apte M; Davis TP; Morton JP; Haghighi K; Phillips PA, 2020, Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition, http://dx.doi.org/10.1101/2020.07.12.199638
    Conference Papers | 2018
    Ong KL; McClelland RL; Allison MA; Kokkinos J; Wu BJ; Barter PJ; Rye K-A, 2018, 'Association of Elevated Circulating Fibroblast Growth Factor 21 Levels With Prevalent and Incident Metabolic Syndrome: The Multi-Ethnic Study of Atherosclerosis.', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000528619400097&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

  • Outstanding Contribution to Research Award, Faculty of Medicine & Health UNSW
  • Young Investigator Award, American Pancreatic Association
  • Outstanding Achievement in Research Award, Australian Society for Medical Research
  • Winner at UNSW 3-Minute Thesis Final 2019
  • Health & Medical Research Early Career Award – Open Junior Division, Tow Coast Association
  • Bioscience Reports Best Poster Award, Avner Pancreatic Cancer Foundation
  • Tour de Cure PhD Support Scholarship
  • UNSW Scientia PhD Scholarship
  • Shortlisted by UNSW for CSL Florey Next Generation Award

Pancreatic cancer is the deadliest of all major cancers. A major driver of the aggressive nature of this hideous disease is the dense fibrotic scar tissue surrounding pancreatic tumours which acts like a fortress to protect and support the tumour. John's PhD developed an innovative method to grow whole pieces of human pancreatic tumours in the lab, thus mimicking the tumour and its surrounding 'fortress'. Down the track, this breakthrough will allow researchers to test chemotherapy drugs on each patient's individual tumour to inform personalised treatment for pancreatic cancer. Our multidisciplinary team is also developing a state-of-the-art nanomedicine to break through the tumour 'fortress' and deliver death signals to pancreatic cancer cells.